Active Ingredient(s)	Crizotinib
Manufacturer	Beacon
Country of Origin	Bangladesh
Reference	N/A

What is Crizonix (Crizotinib) used for?

Crizonix is a medicine used to treat cancer. Specifically, it is used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS 1 positive. The active ingredient in Crizonix is called Crizotinib. Crizotinib is an oral receptor tyrosine kinase inhibitor.

How should I use Crizonix (Crizotinib)?

Crizonix is packaged in a box of 28 capsules, each capsule containing 250mg of Crizotinib.

Your doctor should advise you on the correct dosage of Crizonix to take, how often to take Crizotinib, when to take Crizotinib and how long to take Crizotinib for.

What are the side effects of Crizonix (Crizotinib)?

Crizotinib can result in some unwanted side effects, the most common of which are:

• upper respiratory infection
• nausea
• vomiting
• stomach pain
• decreased appetite
• insomnia
• dizziness
• tired feeling
• diarrhea
• constipation
• rash or itching
• cold symptoms (stuffy nose, sneezing, sore throat)
• numbness or tingling
• swelling in your hands or feet

Stop using Crizonix and call your doctor immediately if you notice any serious side effects such as:

• severe dizziness, fainting, fast or pounding heartbeats;
• vision problems such as blurred vision, increased sensitivity of your eyes to light, or seeing flashes of light or "floaters";
• chest pain, dry cough or cough with mucus, wheezing, feeling short of breath;
• easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
• fever, chills, body aches, flu symptoms, sores in your mouth and throat; or
• nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Other serious side effects Crizotinib can cause include pneumonitis, QT prolongation and hepatic alterations.

Please Note

Crizonix can be used by adults with ALK-positive advanced NSCLC (non-small cell lung cancer) or with previously treated ALK-positive advanced NSCLC & ROS1 (+) NSCLC.